C-peptide vs PACAP-38
Head-to-head comparison of C-peptide (Connecting peptide (C-peptide)) and PACAP-38 (Pituitary Adenylate Cyclase-Activating Polypeptide-38 (human PACAP-38)) — benefits, dosing, side effects, research data, and where to buy.
| Property | C-peptide | PACAP-38 |
|---|---|---|
| Category | Pain Management | Cognitive Enhancement |
| Full Name | Connecting peptide (C-peptide) | Pituitary Adenylate Cyclase-Activating Polypeptide-38 (human PACAP-38) |
| Molecular Weight | 3020.3 Da | 4534 Da |
| Half-Life | ~20-30 min | minutes |
| Amino Acids | 31 | 38 aa |
| Typical Dose | no approved analgesic dose|research-only | 10-100 µg preclinical range |
| Route | IV|subQ | Intranasal |
| Purity | ≥98% | ≥98% |
| Studies Count | 46 | 650 |
| Research Status | Pre-clinical | Pre-clinical |
C-peptide Benefits
- ✓diabetic neuropathy research
- ✓nerve function support
- ✓possible analgesic effect
PACAP-38 Benefits
- ✓synaptic plasticity
- ✓BDNF upregulation
- ✓neuroprotection
- ✓memory consolidation
C-peptide Dosing
0.5-1.0 mg/day in research|route varies by protocol
PACAP-38 Dosing
0.1-1 nmol ICV in rodents|10-100 µg intranasal in preclinical studies|single-dose or short repeated protocols
C-peptide Side Effects
- ⚠injection-site reactions
- ⚠unknown long-term safety
PACAP-38 Side Effects
- ⚠headache-like effects
- ⚠flushing
- ⚠hypotension
Research Overview
C-peptide
C-peptide is not an approved analgesic, but multiple studies have examined its effects on peripheral nerve blood flow and neuropathy outcomes. The strongest relevance is in diabetic neuropathic pain rather than migraine.
PACAP-38
PACAP-38 is one of the most studied endogenous neuropeptides for protecting neurons from ischemic and excitotoxic damage. Preclinical literature also links it to hippocampal plasticity and learning-related signaling, including increased BDNF expression.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.